Cyclerion Therapeutics, Inc. (KRSA): key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Revenue (FY2025)
- $2.1M
- Net Income/Loss (FY2025)
- -$3.5M
- Total Assets (FY2025)
- $10.0M
- Total Equity (FY2025)
- $9.1M
- Cash Flows from Operating Activities (FY2025)
- -$3.3M
Source: Cyclerion Therapeutics, Inc. 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
